PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-30.79%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-31.28%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-21.00%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-22.22%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
7.78%
Share count expansion well above RVPH's 0.10%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.68%
Diluted share count expanding well above RVPH's 0.10%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-4.39%
Negative OCF growth while RVPH is at 796.90%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-4.24%
Negative FCF growth while RVPH is at 796.90%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7210.53%
Negative 10Y OCF/share CAGR while RVPH stands at 769.60%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
76.96%
Below 50% of RVPH's 769.60%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
70.68%
3Y OCF/share CAGR under 50% of RVPH's 769.60%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-11609.25%
Negative 10Y net income/share CAGR while RVPH is at 769.60%. Joel Greenblatt sees a major red flag in long-term profit erosion.
81.05%
Below 50% of RVPH's 769.60%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
70.82%
Below 50% of RVPH's 769.60%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
881.79%
Equity/share CAGR of 881.79% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-26.92%
Negative 5Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-79.64%
Negative 3Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
Negative asset growth while RVPH invests at 0.94%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-41.29%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-11.75%
We’re deleveraging while RVPH stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
20.45%
R&D growth of 20.45% while RVPH is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
69.30%
SG&A growth of 69.30% while RVPH is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.